The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Propensity score (PS) comparison between lisocabtagene maraleucel (liso-cel) plus ibrutinib combination therapy (combo) and liso-cel monotherapy (mono) cohorts from TRANSCEND CLL.
 
William Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Kite, a Gilead company; Loxo; MDACC Cancer Center Support Grant; NIH/NCI award number CA016672; Novartis; Numab; Nurix; Oncternal Therapeutics, Inc; Pharmacyclics; Xencor
 
Kathleen Dorritie
Honoraria - Cancer Network; Clinical Care Options; DAVA Pharmaceuticals; MJH Life Sciences; Onc Live
Consulting or Advisory Role - Janssen
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche; Genmab/Seattle Genetics; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company
 
Jordan Gauthier
Consulting or Advisory Role - Century Therapeutics
Research Funding - Sobi, Juno Therapeutics (a BMS company), Celgene (a BMS company), Angiocrine Bioscience, Faron Pharmaceuticals, CARGO Therapeutics, CytoAgents
 
Jacob Soumerai
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb; Genentech/Roche; Seagen
Research Funding - Adaptive Biotechnologies; BeiGene; BostonGene; Genentech/Roche; GlaxoSmithKline; Moderna Therapeutics; Takeda; TG Therapeutics
 
Saad Kenderian
Stock and Other Ownership Interests - LeahLabs, Chymal
Consulting or Advisory Role - Kite/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno/BMS, Capstan Bio, Carisma, Torque, and Novartis
Research Funding - Kite, Gilead, Juno, BMS, Novartis, Humanigen, MorphoSys, Tolero, Sunesis/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen
Patents, Royalties, Other Intellectual Property - Novartis, Humanigen, Immix
 
Rajneesh Nath
Stock and Other Ownership Interests - Pfizer
Honoraria - ADC Therapeutics; Alimera Sciences; Allovir; Autlous; Bristol-Myers Squibb/Celgene/Juno; Incyte
Consulting or Advisory Role - Actinium Pharmaceuticals
 
Peter Riedell
Honoraria - Novartis
Consulting or Advisory Role - Abbvie; ADC Therapeutics; BeiGene; Bristol-Myers Squibb/Celgene; CVS; Genentech/Roche; Genmab; Intellia Therapeutics; Kite, a Gilead company; Nektar; Novartis; Pharmacyclics/Janssen; Sana Biotechnology
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Calibr (Inst); Cellectis (Inst); crispr therapeutics (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Tessa Therapeutics (Inst); Xencor (Inst)
 
Danielle Brander
Honoraria - BeiGene; Pharmacyclics
Consulting or Advisory Role - Genentech/Abbvie; Pharmacyclics
Research Funding - Abbvie (Inst); ArQule (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Catapult Therapeutics (Inst); DTRM (Inst); Genentech (Inst); MEI Pharma (Inst); Newave Pharmaceutical (Inst); Novartis (Inst); Nurix; Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Daniel Ermann
Consulting or Advisory Role - Bengene, ADC theraputics
Speakers' Bureau - AstraZeneca
 
Nirav Shah
Stock and Other Ownership Interests - Tundra Targeted Therapeutics
Consulting or Advisory Role - Abbvie; BeiGene; CARGO Therapeutics; Galapagos NV; Incyte; Janssen Oncology; Juno/Bristol-Myers Sqibb; Kite, a Gilead company; Loxo/Lilly; Novartis; Seagen
Research Funding - Adaptive Biotechnologies; Genentech; Loxo/Lilly; Miltenyi Biotec
Travel, Accommodations, Expenses - Loxo/Lilly; Miltenyi Biomedicine
 
San-San Ou
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sanhita Sengupta
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Pradipta Ray
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb; Doloromics
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Jixian Wang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sherilyn Tuazon
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Revathi Ananthakrishnan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Tanya Siddiqi
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Kite, a Gilead company
Research Funding - Acerta Pharma (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)